In January 2020, the World Health Organization announced the discovery of a new virus causing infectious respiratory disease.
This virus, called COVID-19 (or SARS-CoV-2), is a new coronavirus differing from the viruses responsible for the SARS outbreak in 2003 and for the MERS outbreak.
Researchers all over the world are involved in the research for a new solutions aiming at:
detecting the virus
mitigating the propagation of the virus
curing infected people
Fighting against the COVID-19 pandemic ? ProteoGenix accelerates your immunodiagnostic, vaccine and therapeutic development thanks to a large catalog of ready-to-use COVID-19 products.
This catalog comprises:
COVID-19 antigens containing a large choice of COVID-19 peptides and proteins. This includes structural and non-structural proteins and fragments such as the Spike protein (S protein, full length, subunits or fragments), the nucleocapsid protein (N protein), 2′-O-methyltransferase (nsp16), RNA-directed RNA polymerase (RdRp, nsp12) among others…
COVID-19 antibodies including anti-SARS-CoV antibodies(2003) cross-reacting with the current COVID-19 as well as anti-S1 and anti-NSP antibodies generated
